BioLingus (Cayman) Ltd. SUBL 深 沪
已收盘 01-11 16:00:00 美东时间
0.00
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.00
- 总市值 0
- 52周最高 0.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.00
- 委 比 0.00%
- 总股本 1300.00万
- 历史最高 0.00
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 0.00
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Indivior Appoints Tony Kingsley to the Board of Directors
RICHMOND, Va., June 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Tony Kingsley to the Board of Directors as an Independent Non-Executive Dire...
06-25 04:12
Indivior Presents Data Showing 300 mg SUBLOCADE May Improve Outcomes For Opioid Use Disorder Patients With Heavy Fentanyl Use
A post-hoc analysis demonstrates that buprenorphine exposure with 300 mg SUBLOCADE® (buprenorphine extended-release) may improve treatment outcomes among opioid use disorder (OUD) patients with heavy fentanyl
06-19 21:02
Indivior To Delist From LSE, Citing US Revenue Dominance And Higher Nasdaq Liquidity In Move To Streamline Operations
In further consideration of Indivior's listing structure, the Board now believes that the London Delisting will be beneficial for the following reasons:Fully aligns with Indivior's most attractive and valuable
06-02 14:05
Indivior Announces Patrick Barry as Chief Commercial Officer
Seasoned commercial executive with more than 30 years of pharmaceutical experience RICHMOND, Va., May 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the appointment...
05-27 20:30
Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection
Rapid Initiation Protocol Reduces Time to Treatment with SUBLOCADE® From One Week to One Hour, A Significant Advancement in the Treatment of Moderate to Severe Opioid Use Disorder (OUD) RICH...
02-24 15:00
Indivior targets $1.5B peak revenue for Sublocade amid 2025 transition plans
Earnings Call Insights: Indivior PLC (NASDAQ:INDV) Q4 2024 Management View The CEO highlighted that 2024 ended with SUBLOCADE achieving 20% net revenue growth despite challenges, including competition...
02-21 03:27
美股异动丨Q3业绩强劲，Indivior盘前涨超8%
格隆汇10月24日｜英国药品集团Indivior(INDV.US)盘前涨超8%。该公司第三季度表现出色，净收入增长13%至3.07亿美元，主要SUBLOCAD...
2024-10-24 17:27
What's Going On With Pfizer Stock On Thursday?
Starboard Value engages with Pfizer's leadership amid growing concerns over the company's trajectory. Meanwhile, Pfizer reports a significant survival benefit in prostate cancer patients from its TALAPRO-2 study, furthering the impact of Talzenna in combination with Xtandi.
2024-10-10 22:44
Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details
Indivior cuts FY24 net revenue outlook due to competition and funding delays, causing a drop in share price.
2024-10-10 21:28
Indivior Announces Share Buyback and Q2 Growth
Indivior (GB:INDV) has released an update. Indivior PLC reports a 24% increase ...
2024-07-25 15:23
